Clinical Trial: Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic
Brief Summary: To study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.
Detailed Summary:
Sponsor: University of Colorado, Denver
Current Primary Outcome:
- Event-free Survival [ Time Frame: up to 5 years ]MRIs of the head and spine
- Overall Survival [ Time Frame: up to 5 years ]
- Intellectual Competence measured by number of cognitive deficits [ Time Frame: up to 5 years ]Neuropsychological testing will be performed 3-6 months after radiation in completed.
Original Primary Outcome:
- Event-free Survival [ Time Frame: up to 5 years ]MRIs of the head and spine
- Overall Survival [ Time Frame: up to 5 years ]
- Intellectual Competence measured by number of cognitive deficits [ Time Frame: up to 5 years ]Neurophsychological testing will be performed 3-6 months after radiation in completed.
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University of Colorado, Denver
Dates:
Date Received: February 27, 2012
Date Started: May 2007
Date Completion: December 2017
Last Updated: December 14, 2016
Last Verified: December 2016
